Skip to main content
PMC home page
Protein Science : A Publication of the Protein Society logoLink to Protein Science : A Publication of the Protein Society
. 1994 Dec;3(12):2254–2271. doi: 10.1002/pro.5560031211

The isomorphous structures of prethrombin2, hirugen-, and PPACK-thrombin: changes accompanying activation and exosite binding to thrombin.

J Vijayalakshmi 1, K P Padmanabhan 1, K G Mann 1, A Tulinsky 1
PMCID: PMC2142772  PMID: 7756983

Abstract

The X-ray crystal structure of prethrombin2 (pre2), the immediate inactive precursor of alpha-thrombin, has been determined at 2.0 A resolution complexed with hirugen. The structure has been refined to a final R-value of 0.169 using 14,211 observed reflections in the resolution range 8.0-2.0 A. A total of 202 water molecules have also been located in the structure. Comparison with the hirugen-thrombin complex showed that, apart from the flexible beginning and terminal regions of the molecule, there are 4 polypeptide segments in pre2 differing in conformation from the active enzyme (Pro 186-Asp 194, Gly 216-Gly 223, Gly 142-Pro 152, and the Arg 15-Ile 16 cleavage region). The formation of the Ile 16-Asp 194 ion pair and the specificity pocket are characteristic of serine protease activation with the conformation of the catalytic triad being conserved. With the determination of isomorphous structures of hirugen-thrombin and D-Phe-Pro-Arg chloromethyl ketone (PPACK)-thrombin, the changes that occur in the active site that affect the kinetics of chromogenic substrate hydrolysis on binding to the fibrinogen recognition exosite have been determined. The backbone of the Ala 190-Gly 197 segment in the active site has an average RMS difference of 0.55 A between the 2 structures (about 3.7 sigma compared to the bulk structure). This segment has 2 type II beta-bends, the first bend showing the largest shift due to hirugen binding. Another important feature was the 2 different conformations of the side chain of Glu 192. The side chain extends to solvent in hirugen-thrombin, which is compatible with the binding of substrates having an acidic residue in the P3 position (protein-C, thrombin platelet receptor). In PPACK-thrombin, the side chain of Asp 189 and the segment Arg 221A-Gly 223 move to provide space for the inhibitor, whereas in hirugen-thrombin, the Ala 190-Gly 197 movement expands the active site region. Although 8 water molecules are expelled from the active site with PPACK binding, the inhibitor complex is resolvated with 5 other water molecules.

Full Text

The Full Text of this article is available as a PDF (3.5 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arni R. K., Padmanabhan K., Padmanabhan K. P., Wu T. P., Tulinsky A. Structures of the noncovalent complexes of human and bovine prothrombin fragment 2 with human PPACK-thrombin. Biochemistry. 1993 May 11;32(18):4727–4737. doi: 10.1021/bi00069a006. [DOI] [PubMed] [Google Scholar]
  2. Bode W., Huber R. Crystal structure analysis and refinement of two variants of trigonal trypsinogen: trigonal trypsin and PEG (polyethylene glycol) trypsinogen and their comparison with orthorhombic trypsin and trigonal trypsinogen. FEBS Lett. 1978 Jun 15;90(2):265–269. doi: 10.1016/0014-5793(78)80382-2. [DOI] [PubMed] [Google Scholar]
  3. Bode W., Mayr I., Baumann U., Huber R., Stone S. R., Hofsteenge J. The refined 1.9 A crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J. 1989 Nov;8(11):3467–3475. doi: 10.1002/j.1460-2075.1989.tb08511.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bode W., Turk D., Karshikov A. The refined 1.9-A X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships. Protein Sci. 1992 Apr;1(4):426–471. doi: 10.1002/pro.5560010402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chang J. Y. The structures and proteolytic specificities of autolysed human thrombin. Biochem J. 1986 Dec 15;240(3):797–802. doi: 10.1042/bj2400797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Church F. C., Pratt C. W., Noyes C. M., Kalayanamit T., Sherrill G. B., Tobin R. B., Meade J. B. Structural and functional properties of human alpha-thrombin, phosphopyridoxylated alpha-thrombin, and gamma T-thrombin. Identification of lysyl residues in alpha-thrombin that are critical for heparin and fibrin(ogen) interactions. J Biol Chem. 1989 Nov 5;264(31):18419–18425. [PubMed] [Google Scholar]
  7. Crawford J. L., Lipscomb W. N., Schellman C. G. The reverse turn as a polypeptide conformation in globular proteins. Proc Natl Acad Sci U S A. 1973 Feb;70(2):538–542. doi: 10.1073/pnas.70.2.538. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Downing M. R., Butkowski R. J., Clark M. M., Mann K. G. Human prothrombin activation. J Biol Chem. 1975 Dec 10;250(23):8897–8906. [PubMed] [Google Scholar]
  9. Ehrlich H. J., Grinnell B. W., Jaskunas S. R., Esmon C. T., Yan S. B., Bang N. U. Recombinant human protein C derivatives: altered response to calcium resulting in enhanced activation by thrombin. EMBO J. 1990 Aug;9(8):2367–2373. doi: 10.1002/j.1460-2075.1990.tb07411.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Esmon C. T. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem. 1989 Mar 25;264(9):4743–4746. [PubMed] [Google Scholar]
  11. Fenton J. W., 2nd, Fasco M. J., Stackrow A. B. Human thrombins. Production, evaluation, and properties of alpha-thrombin. J Biol Chem. 1977 Jun 10;252(11):3587–3598. [PubMed] [Google Scholar]
  12. Fenton J. W., 2nd Thrombin specificity. Ann N Y Acad Sci. 1981;370:468–495. doi: 10.1111/j.1749-6632.1981.tb29757.x. [DOI] [PubMed] [Google Scholar]
  13. Fenton J. W., 2nd Thrombin. Ann N Y Acad Sci. 1986;485:5–15. doi: 10.1111/j.1749-6632.1986.tb34563.x. [DOI] [PubMed] [Google Scholar]
  14. Freer S. T., Kraut J., Robertus J. D., Wright H. T., Xuong N. H. Chymotrypsinogen: 2.5-angstrom crystal structure, comparison with alpha-chymotrypsin, and implications for zymogen activation. Biochemistry. 1970 Apr 28;9(9):1997–2009. doi: 10.1021/bi00811a022. [DOI] [PubMed] [Google Scholar]
  15. Henderson R. Structure of crystalline alpha-chymotrypsin. IV. The structure of indoleacryloyl-alpha-chyotrypsin and its relevance to the hydrolytic mechanism of the enzyme. J Mol Biol. 1970 Dec 14;54(2):341–354. doi: 10.1016/0022-2836(70)90434-1. [DOI] [PubMed] [Google Scholar]
  16. Hortin G. L., Trimpe B. L. Allosteric changes in thrombin's activity produced by peptides corresponding to segments of natural inhibitors and substrates. J Biol Chem. 1991 Apr 15;266(11):6866–6871. [PubMed] [Google Scholar]
  17. Hubbard S. J., Campbell S. F., Thornton J. M. Molecular recognition. Conformational analysis of limited proteolytic sites and serine proteinase protein inhibitors. J Mol Biol. 1991 Jul 20;220(2):507–530. doi: 10.1016/0022-2836(91)90027-4. [DOI] [PubMed] [Google Scholar]
  18. Hubbard S. J., Eisenmenger F., Thornton J. M. Modeling studies of the change in conformation required for cleavage of limited proteolytic sites. Protein Sci. 1994 May;3(5):757–768. doi: 10.1002/pro.5560030505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Huber R., Kukla D., Bode W., Schwager P., Bartels K., Deisenhofer J., Steigemann W. Structure of the complex formed by bovine trypsin and bovine pancreatic trypsin inhibitor. II. Crystallographic refinement at 1.9 A resolution. J Mol Biol. 1974 Oct 15;89(1):73–101. doi: 10.1016/0022-2836(74)90163-6. [DOI] [PubMed] [Google Scholar]
  20. Krishnaswamy S., Church W. R., Nesheim M. E., Mann K. G. Activation of human prothrombin by human prothrombinase. Influence of factor Va on the reaction mechanism. J Biol Chem. 1987 Mar 5;262(7):3291–3299. [PubMed] [Google Scholar]
  21. Krstenansky J. L., Broersma R. J., Owen T. J., Payne M. H., Yates M. T., Mao S. J. Development of MDL 28,050, a small stable antithrombin agent based on a functional domain of the leech protein, hirudin. Thromb Haemost. 1990 Apr 12;63(2):208–214. [PubMed] [Google Scholar]
  22. Le Bonniec B. F., Esmon C. T. Glu-192----Gln substitution in thrombin mimics the catalytic switch induced by thrombomodulin. Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7371–7375. doi: 10.1073/pnas.88.16.7371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Liu L. W., Vu T. K., Esmon C. T., Coughlin S. R. The region of the thrombin receptor resembling hirudin binds to thrombin and alters enzyme specificity. J Biol Chem. 1991 Sep 15;266(26):16977–16980. [PubMed] [Google Scholar]
  24. Liu L. W., Ye J., Johnson A. E., Esmon C. T. Proteolytic formation of either of the two prothrombin activation intermediates results in formation of a hirugen-binding site. J Biol Chem. 1991 Dec 15;266(35):23633–23636. [PubMed] [Google Scholar]
  25. Madison E. L., Kobe A., Gething M. J., Sambrook J. F., Goldsmith E. J. Converting tissue plasminogen activator to a zymogen: a regulatory triad of Asp-His-Ser. Science. 1993 Oct 15;262(5132):419–421. doi: 10.1126/science.8211162. [DOI] [PubMed] [Google Scholar]
  26. Mann K. G. Prothrombin. Methods Enzymol. 1976;45:123–156. doi: 10.1016/s0076-6879(76)45016-4. [DOI] [PubMed] [Google Scholar]
  27. Mao S. J., Yates M. T., Owen T. J., Krstenansky J. L. Interaction of hirudin with thrombin: identification of a minimal binding domain of hirudin that inhibits clotting activity. Biochemistry. 1988 Oct 18;27(21):8170–8173. doi: 10.1021/bi00421a027. [DOI] [PubMed] [Google Scholar]
  28. Maryanoff B. E., Qiu X., Padmanabhan K. P., Tulinsky A., Almond H. R., Jr, Andrade-Gordon P., Greco M. N., Kauffman J. A., Nicolaou K. C., Liu A. Molecular basis for the inhibition of human alpha-thrombin by the macrocyclic peptide cyclotheonamide A. Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):8048–8052. doi: 10.1073/pnas.90.17.8048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Mathews I. I., Padmanabhan K. P., Ganesh V., Tulinsky A., Ishii M., Chen J., Turck C. W., Coughlin S. R., Fenton J. W., 2nd Crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes. Biochemistry. 1994 Mar 22;33(11):3266–3279. doi: 10.1021/bi00177a018. [DOI] [PubMed] [Google Scholar]
  30. Naski M. C., Fenton J. W., 2nd, Maraganore J. M., Olson S. T., Shafer J. A. The COOH-terminal domain of hirudin. An exosite-directed competitive inhibitor of the action of alpha-thrombin on fibrinogen. J Biol Chem. 1990 Aug 15;265(23):13484–13489. [PubMed] [Google Scholar]
  31. Ni F., Ripoll D. R., Martin P. D., Edwards B. F. Solution structure of a platelet receptor peptide bound to bovine alpha-thrombin. Biochemistry. 1992 Nov 24;31(46):11551–11557. doi: 10.1021/bi00161a037. [DOI] [PubMed] [Google Scholar]
  32. Padmanabhan K., Padmanabhan K. P., Tulinsky A., Park C. H., Bode W., Huber R., Blankenship D. T., Cardin A. D., Kisiel W. Structure of human des(1-45) factor Xa at 2.2 A resolution. J Mol Biol. 1993 Aug 5;232(3):947–966. doi: 10.1006/jmbi.1993.1441. [DOI] [PubMed] [Google Scholar]
  33. Parry M. A., Stone S. R., Hofsteenge J., Jackman M. P. Evidence for common structural changes in thrombin induced by active-site or exosite binding. Biochem J. 1993 Mar 15;290(Pt 3):665–670. doi: 10.1042/bj2900665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Priestle J. P., Rahuel J., Rink H., Tones M., Grütter M. G. Changes in interactions in complexes of hirudin derivatives and human alpha-thrombin due to different crystal forms. Protein Sci. 1993 Oct;2(10):1630–1642. doi: 10.1002/pro.5560021009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Qiu X., Yin M., Padmanabhan K. P., Krstenansky J. L., Tulinsky A. Structures of thrombin complexes with a designed and a natural exosite peptide inhibitor. J Biol Chem. 1993 Sep 25;268(27):20318–20326. [PubMed] [Google Scholar]
  36. Robertus J. D., Kraut J., Alden R. A., Birktoft J. J. Subtilisin; a stereochemical mechanism involving transition-state stabilization. Biochemistry. 1972 Nov 7;11(23):4293–4303. doi: 10.1021/bi00773a016. [DOI] [PubMed] [Google Scholar]
  37. Rydel T. J., Ravichandran K. G., Tulinsky A., Bode W., Huber R., Roitsch C., Fenton J. W., 2nd The structure of a complex of recombinant hirudin and human alpha-thrombin. Science. 1990 Jul 20;249(4966):277–280. doi: 10.1126/science.2374926. [DOI] [PubMed] [Google Scholar]
  38. Rydel T. J., Tulinsky A., Bode W., Huber R. Refined structure of the hirudin-thrombin complex. J Mol Biol. 1991 Sep 20;221(2):583–601. doi: 10.1016/0022-2836(91)80074-5. [DOI] [PubMed] [Google Scholar]
  39. Rydel T. J., Yin M., Padmanabhan K. P., Blankenship D. T., Cardin A. D., Correa P. E., Fenton J. W., 2nd, Tulinsky A. Crystallographic structure of human gamma-thrombin. J Biol Chem. 1994 Sep 2;269(35):22000–22006. [PubMed] [Google Scholar]
  40. Schechter I., Berger A. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun. 1967 Apr 20;27(2):157–162. doi: 10.1016/s0006-291x(67)80055-x. [DOI] [PubMed] [Google Scholar]
  41. Skrzypczak-Jankun E., Carperos V. E., Ravichandran K. G., Tulinsky A., Westbrook M., Maraganore J. M. Structure of the hirugen and hirulog 1 complexes of alpha-thrombin. J Mol Biol. 1991 Oct 20;221(4):1379–1393. [PubMed] [Google Scholar]
  42. Skrzypczak-Jankun E., Rydel T. J., Tulinsky A., Fenton J. W., 2nd, Mann K. G. Human D-Phe-Pro-Arg-CH2-alpha-thrombin crystallization and diffraction data. J Mol Biol. 1989 Apr 20;206(4):755–757. doi: 10.1016/0022-2836(89)90582-2. [DOI] [PubMed] [Google Scholar]
  43. Stevens W. K., Nesheim M. E. Structural changes in the protease domain of prothrombin upon activation as assessed by N-bromosuccinimide modification of tryptophan residues in prethrombin-2 and thrombin. Biochemistry. 1993 Mar 23;32(11):2787–2794. doi: 10.1021/bi00062a008. [DOI] [PubMed] [Google Scholar]
  44. Thaller C., Eichele G., Weaver L. H., Wilson E., Karlsson R., Jansonius J. N. Diffraction methods for biological macromolecules. Seed enlargement and repeated seeding. Methods Enzymol. 1985;114:132–135. doi: 10.1016/0076-6879(85)14011-5. [DOI] [PubMed] [Google Scholar]
  45. Venkatachalam C. M. Stereochemical criteria for polypeptides and proteins. V. Conformation of a system of three linked peptide units. Biopolymers. 1968 Oct;6(10):1425–1436. doi: 10.1002/bip.1968.360061006. [DOI] [PubMed] [Google Scholar]
  46. Wang D., Bode W., Huber R. Bovine chymotrypsinogen A X-ray crystal structure analysis and refinement of a new crystal form at 1.8 A resolution. J Mol Biol. 1985 Oct 5;185(3):595–624. doi: 10.1016/0022-2836(85)90074-9. [DOI] [PubMed] [Google Scholar]
  47. Wright H. T. Activation of chymotrypsinogen-A. An hypothesis based upon comparison of the crystal structures of chymotrypsinogen-A and alpha-chymotrypsin. J Mol Biol. 1973 Sep 5;79(1):13–23. doi: 10.1016/0022-2836(73)90266-0. [DOI] [PubMed] [Google Scholar]
  48. Wu Q., Picard V., Aiach M., Sadler J. E. Activation-induced exposure of the thrombin anion-binding exosite. Interactions of recombinant mutant prothrombins with thrombomodulin and a thrombin exosite-specific antibody. J Biol Chem. 1994 Feb 4;269(5):3725–3730. [PubMed] [Google Scholar]
  49. Zdanov A., Wu S., DiMaio J., Konishi Y., Li Y., Wu X., Edwards B. F., Martin P. D., Cygler M. Crystal structure of the complex of human alpha-thrombin and nonhydrolyzable bifunctional inhibitors, hirutonin-2 and hirutonin-6. Proteins. 1993 Nov;17(3):252–265. doi: 10.1002/prot.340170304. [DOI] [PubMed] [Google Scholar]

Articles from Protein Science : A Publication of the Protein Society are provided here courtesy of The Protein Society

RESOURCES